Gout therapeutics and drug delivery.
Advanced therapeutics
Drug delivery systems
Gout
Hyperuricemia
Inorganic carriers
Lipid carriers
Nanoparticles
Polymeric carriers
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
28
05
2023
revised:
02
09
2023
accepted:
04
09
2023
medline:
13
10
2023
pubmed:
11
9
2023
entrez:
10
9
2023
Statut:
ppublish
Résumé
Gout is a common inflammatory arthritis caused by persistently elevated uric acid levels. With the improvement of people's living standards, the consumption of processed food and the widespread use of drugs that induce elevated uric acid, gout rates are increasing, seriously affecting the human quality of life, and becoming a burden to health systems worldwide. Since the pathological mechanism of gout has been elucidated, there are relatively effective drug treatments in clinical practice. However, due to (bio)pharmaceutical shortcomings of these drugs, such as poor chemical stability and limited ability to target the pathophysiological pathways, traditional drug treatment strategies show low efficacy and safety. In this scenario, drug delivery systems (DDS) design that overcome these drawbacks is urgently called for. In this review, we initially describe the pathological features, the therapeutic targets, and the drugs currently in clinical use and under investigation to treat gout. We also comprehensively summarize recent research efforts utilizing lipid, polymeric and inorganic carriers to develop advanced DDS for improved gout management and therapy.
Identifiants
pubmed: 37690697
pii: S0168-3659(23)00597-7
doi: 10.1016/j.jconrel.2023.09.011
pii:
doi:
Substances chimiques
Uric Acid
268B43MJ25
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
728-754Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.